Loading organizations...
Based in Japan, Curreio is a biotechnology company that specializes in structure-based drug discovery utilizing cryo-electron microscopy for the high-accuracy 3D structural analysis of complex proteins. The organization operates a proprietary technological platform designed to target challenging biological structures, including transmembrane proteins, to facilitate the development of novel therapeutics. Curreio engages in joint research partnerships and service-based collaborations with pharmaceutical firms, academic institutions, and technology companies such as Veneno Technologies and Nagoya University. Backed by an undisclosed amount of Series A venture funding, the company employs a specialized drug discovery team that includes former research chemists from Sosei Group Corporation. The firm's current research initiatives focus heavily on the joint development of disulfide-rich peptides and small-molecule pharmaceutical drugs. Curreio was established in August 2019 and is currently led by Chief Executive Officer Motoki Nakai.
Curreio has raised $2.0M across 1 funding round.
Curreio has raised $2.0M in total across 1 funding round.
Curreio has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Series A in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 22, 2023 | $2M Series A | — | 3S Capital, Asahi Kasei Pharma, Takehiko Sawabe, Dojin Capital, Ikerunippon Capital Partners, ONO Venture Investment, Kamada, U Tokyo Entrepreneur Supporter | Announced |
Curreio has raised $2.0M in total across 1 funding round.
Curreio's investors include 3S Capital, Asahi Kasei Pharma, Takehiko Sawabe, DOJIN Capital, IKERUNippon Capital Partners, Ono Venture Investment, Kamada, U-Tokyo Entrepreneur Supporter.
